Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Bispecific monoclonal antibodies (bsAbs) are now a core treatment class in relapsed/refractory multiple myeloma, especially as “off-the-shelf” T-cell–redirecting therapies targeting antigens such as BCMA and GPRC5D on plasma cells plus CD3 on T cells. For plasmacytoma, they are not a separate established disease-specific class; their role is mainly inferred when plasmacytoma represents myeloma involvement, particularly extramedullary disease, rather than as standard therapy for solitary plasmacytoma.
see also:
Cancer Immunotherapy / Immuno-Oncology & Multiple Myeloma (MM) / Plasmocytoma
[Multiple Myeloma…